Drug Combination Details
General Information of the Combination (ID: C03422) | |||||
---|---|---|---|---|---|
Name | Vanillic acid NP Info | + | Doxorubicin Drug Info | ||
Structure | + | ||||
Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Decreasing Adverse Drug Reaction by This Combination | ||||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | TLR4 | Molecule Info |
Pathway MAP
|
|
In-vivo Model | Male Wistar albino rats weighing 200 +/- 20 g were used in this study. | |||||
Experimental
Result(s) |
VA exerts cardioprotective effects against DOX-induced cardiotoxicity by decreasing oxidative stress and biomarkers of cardiotoxicity, suppression of TLR4 signaling and consequently inflammation pathway. |
References | ||||
---|---|---|---|---|
Reference 1 | Cardioprotective effect of vanillic acid against doxorubicin-induced cardiotoxicity in rat. Res Pharm Sci. 2020 Feb 20;15(1):87-96. |